



This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Financings in Brief: NeuroControl

This article was originally published in The Gray Sheet

03 Mar 1997 | **NEWS**

Executive Summary

NeuroControl: Receives \$7.6 mil. in additional equity funding from existing and new investors. New investors include: McDonald & Company; Morgenthaler Ventures; Robertson Stephens & Company; and Wessels, Arnold & Henderson. Primus Venture Partners, the Cleveland Clinic Foundation and Invacare increased their stakes in the Cleveland-based firm. A portion of the proceeds will go toward marketing of NeuroControl's Freehand neuroprosthesis following anticipated FDA approval later this year ("The Gray Sheet" Sept. 30, 1996, p. 11). Funds also will go toward consolidating European marketing and completing U.S. clinical trials of the firm's Vocare bladder/bowel control implant ("The Gray Sheet" May 13, 1996, I&W-5). The firm also plans to "build staff, including field representatives worldwide, and accelerate new product development"...

You may also be interested in...

New York's Halt On Sales To Minors Could Catch More Than Weight Loss, Bodybuilding Products

"What are retailers going to do? They're either going to put it behind a case or they're going to put it in a pharmacy-only counter where you have to ask for assistance to get it," says CPN CEO Steve Mister. "Until

Supplement Industry Slams New York's Reasons To Age-Restrict Sales, Expects Other States To Follow

Sales of supplements and OTC drugs labeled for weight loss and bodybuilding supplements in New York will be hit hard by the state's new age-restriction law, industry officials say. The law, which takes effect in January 1997, requires retailers to obtain parental consent for minors to purchase supplements.

Keeping Track: US FDA Drugs Center Passes 50 Novel Agent Approvals In 2023

AstraZeneca's Truqap and Evive's Ryzneuta bring FDA center for drugs' 2023 novel agent total to 51, while biologics center already sits on a record-breaking 14 novel approvals.

Existing Subscriber?

Sign in to continue reading.

SIGN IN

New to Medtech Insight?

Start a free trial today!

FREE TRIAL